GEORGETOWN, Texas (PRWEB) November 27, 2018
A supplier agreement has been signed between ORTHOReBIRTH USA and Resource Optimization & Innovation, LLC, a Missouri-based company that works alongside fellow providers to deliver end-to-end supply chain solutions with significant results. This agreement will go into effect on January 1, 2019.
ORTHOReBIRTH USA markets ReBOSSIS®, the only biosynthetic scaffold with electrospun microfiber construction. Surgeons have been impressed with the superior handling characteristics and the clinical results produced utilizing ReBOSSIS®, and with this partnership, the company is looking forward to more success.
“It is outstanding to be partnering with Resource Optimization & Innovation,” says Doris Blake, COO of ORTHOReBIRTH USA. “ROi is the only provider to be ranked by Gartner as a top 10 health care supply chain for nine consecutive years, so signing this contract was a big step in the right direction for us.”
About Resource Optimization & Innovation, LLC
Resource Optimization & Innovation, LLC was founded more than a decade ago by Mercy, one of the nation’s largest nonprofit health care systems, and now serves fellow providers across the country who share a passion for supply chain excellence. As a provider-owned Accountable Supply Chain Organization™, ROi’s insights and goals are uniquely aligned with today's health care organizations, who all must find new ways to provide better care at lower costs.
About ORTHOReBIRTH USA
We recognize the challenges associated with orthopedic surgery—for patients, surgeons and hospitals alike. We are committed to marketing cutting-edge orthopedic biologics that improve patients’ quality of life and offer superior outcomes. We have carried out extensive studies on what makes biologic materials successful and have used that knowledge to engineer world-class products for use in a host of orthopedic surgical procedures. ORTHOReBIRTH USA is proud to market premium orthopedic biologics to surgeons practicing around the world. Recently, ORTHOReBIRTH USA also signed a letter of intent with Dr. Loubert S. Suddaby to develop new biologics.